Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The last earnings update was 77 days ago. More info.
Add to Portfolio Compare Print
- Minerva Neurosciences has significant price volatility in the past 3 months.
NERV Share Price and Events
7 Day Returns
1 Year Returns
NERV Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Minerva Neurosciences (NERV) | 0.9% | 54.4% | -11.3% | -17.9% | -43.8% | -13.3% |
| US Biotechs | -0.2% | -2.9% | 0.8% | -12.1% | 6.1% | 7.2% |
| US Market | -1.2% | 0.7% | 1.7% | 3.4% | 35.5% | 41.6% |
1 Year Return vs Industry and Market
- NERV underperformed the Biotechs industry which returned -12.1% over the past year.
- NERV underperformed the Market in United States of America which returned 3.4% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Minerva Neurosciences. This is due to cash flow or dividend data being unavailable. The share price is $6.53.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Minerva Neurosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Minerva Neurosciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-1.38 |
| NasdaqGM:NERV Share Price ** | NasdaqGM (2019-07-19) in USD | $6.53 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 35 Publicly-Listed Biotechs Companies | 19.44x |
| United States of America Market PE Ratio | Median Figure of 3,081 Publicly-Listed Companies | 17.87x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Minerva Neurosciences.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGM:NERV Share Price ÷ EPS (both in USD) = 6.53 ÷ -1.38 |
-4.73x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Minerva Neurosciences is loss making, we can't compare its value to the US Biotechs industry average.
- Minerva Neurosciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Minerva Neurosciences's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -4.73x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts |
52.4%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 26 Publicly-Listed Biotechs Companies | 0.79x |
| United States of America Market PEG Ratio | Median Figure of 2,119 Publicly-Listed Companies | 1.57x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Minerva Neurosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Minerva Neurosciences's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $1.98 |
| NasdaqGM:NERV Share Price * | NasdaqGM (2019-07-19) in USD | $6.53 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 437 Publicly-Listed Biotechs Companies | 2.93x |
| United States of America Market PB Ratio | Median Figure of 5,247 Publicly-Listed Companies | 1.79x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGM:NERV Share Price ÷ Book Value per Share (both in USD) = 6.53 ÷ 1.98 |
3.29x |
* Primary Listing of Minerva Neurosciences.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Minerva Neurosciences is overvalued based on assets compared to the US Biotechs industry average.
Value checks
We assess Minerva Neurosciences's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Minerva Neurosciences has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Minerva Neurosciences's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Minerva Neurosciences's earnings growth is expected to exceed the United States of America market average.
- Unable to compare Minerva Neurosciences's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGM:NERV Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts | 52.4% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 23% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 18.5% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 14% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.4% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 477 | 249 | 147 | 2 |
| 2022-12-31 | 259 | -11 | -8 | 2 |
| 2021-12-31 | 53 | -95 | -90 | 2 |
| 2020-12-31 | 0 | -117 | -99 | 3 |
| 2019-12-31 | 0 | -59 | -68 | 3 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | -41 | -54 | |
| 2018-12-31 | -42 | -50 | |
| 2018-09-30 | -41 | -37 | |
| 2018-06-30 | -6 | -36 | |
| 2018-03-31 | -2 | -33 | |
| 2017-12-31 | 3 | -32 | |
| 2017-09-30 | 3 | -41 | |
| 2017-06-30 | -26 | -38 | |
| 2017-03-31 | -26 | -34 | |
| 2016-12-31 | -26 | -31 | |
| 2016-09-30 | -23 | -30 | |
| 2016-06-30 | -24 | -28 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
All data from Minerva Neurosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 2.94 | 5.65 | 0.22 | 2.00 |
| 2022-12-31 | -0.17 | 0.53 | -0.86 | 2.00 |
| 2021-12-31 | -2.09 | -1.95 | -2.23 | 2.00 |
| 2020-12-31 | -2.31 | -1.62 | -3.31 | 3.00 |
| 2019-12-31 | -1.69 | -1.62 | -1.79 | 3.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -1.38 |
| 2018-12-31 | -1.29 |
| 2018-09-30 | -0.95 |
| 2018-06-30 | -0.92 |
| 2018-03-31 | -0.86 |
| 2017-12-31 | -0.83 |
| 2017-09-30 | -1.11 |
| 2017-06-30 | -1.08 |
| 2017-03-31 | -1.00 |
| 2016-12-31 | -0.99 |
| 2016-09-30 | -1.04 |
| 2016-06-30 | -1.04 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Minerva Neurosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Minerva Neurosciences's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Minerva Neurosciences has a total score of 3/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Minerva Neurosciences performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Minerva Neurosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Minerva Neurosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Minerva Neurosciences's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Minerva Neurosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | -53.58 | 17.25 | 38.05 | |
| 2018-12-31 | -50.17 | 16.84 | 34.89 | |
| 2018-09-30 | -36.81 | 15.21 | 32.42 | |
| 2018-06-30 | -36.05 | 13.61 | 33.01 | |
| 2018-03-31 | -33.30 | 12.34 | 31.09 | |
| 2017-12-31 | -31.52 | 10.91 | 30.26 | |
| 2017-09-30 | -41.09 | 10.66 | 30.21 | |
| 2017-06-30 | -38.25 | 10.59 | 27.11 | |
| 2017-03-31 | -33.69 | 10.24 | 22.68 | |
| 2016-12-31 | -31.05 | 9.75 | 20.44 | |
| 2016-09-30 | -30.08 | 8.95 | 20.20 | |
| 2016-06-30 | -27.60 | 8.44 | 18.18 | |
| 2016-03-31 | -28.99 | 8.04 | 19.95 | |
| 2015-12-31 | -27.08 | 7.58 | 18.53 | |
| 2015-09-30 | -26.08 | 10.12 | 15.24 | |
| 2015-06-30 | -47.30 | 10.59 | 36.21 | |
| 2015-03-31 | -60.06 | 11.84 | 46.28 | |
| 2014-12-31 | -56.90 | 11.96 | 42.91 | |
| 2014-09-30 | -51.59 | 9.35 | 40.10 | |
| 2014-06-30 | -24.92 | 7.29 | 15.50 | |
| 2014-03-31 | -5.93 | 4.32 | 1.19 | |
| 2013-12-31 | -3.26 | 2.45 | 0.71 | |
| 2013-09-30 | -1.43 | 0.77 | 0.66 | |
| 2012-12-31 | -1.58 | 1.03 | 0.55 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Minerva Neurosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Minerva Neurosciences has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Minerva Neurosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Minerva Neurosciences's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Minerva Neurosciences has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Minerva Neurosciences's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Minerva Neurosciences's finances.
The net worth of a company is the difference between its assets and liabilities.
- Minerva Neurosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Minerva Neurosciences's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Minerva Neurosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Minerva Neurosciences Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 77.42 | 0.00 | 79.16 |
| 2018-12-31 | 90.26 | 0.00 | 88.00 |
| 2018-09-30 | 101.39 | 0.00 | 97.61 |
| 2018-06-30 | 110.66 | 1.40 | 108.49 |
| 2018-03-31 | 121.29 | 2.70 | 121.00 |
| 2017-12-31 | 131.60 | 3.96 | 128.16 |
| 2017-09-30 | 130.18 | 5.19 | 132.93 |
| 2017-06-30 | 98.03 | 6.39 | 77.57 |
| 2017-03-31 | 106.29 | 7.56 | 85.36 |
| 2016-12-31 | 105.98 | 8.69 | 82.98 |
| 2016-09-30 | 113.14 | 9.80 | 91.85 |
| 2016-06-30 | 120.61 | 10.10 | 97.06 |
| 2016-03-31 | 66.65 | 10.02 | 44.64 |
| 2015-12-31 | 55.32 | 9.94 | 32.20 |
| 2015-09-30 | 63.07 | 9.86 | 37.49 |
| 2015-06-30 | 68.38 | 9.78 | 35.39 |
| 2015-03-31 | 74.44 | 9.71 | 52.20 |
| 2014-12-31 | 51.50 | 0.00 | 18.55 |
| 2014-09-30 | 56.72 | 0.00 | 23.64 |
| 2014-06-30 | 29.23 | 3.39 | 0.48 |
| 2014-03-31 | 34.09 | 0.83 | 2.14 |
| 2013-12-31 | 20.18 | 0.06 | 1.82 |
| 2013-09-30 | 0.73 | 0.00 | 1.10 |
| 2012-12-31 | 0.02 | 0.00 | 0.20 |
- Minerva Neurosciences has no debt.
- Minerva Neurosciences has no debt compared to 5 years ago when it was 2.5%.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Minerva Neurosciences has sufficient cash runway for 1.9 years based on current free cash flow.
- Minerva Neurosciences has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 11.3% each year.
Financial health checks
We assess Minerva Neurosciences's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Minerva Neurosciences has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Minerva Neurosciences's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Minerva Neurosciences
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Minerva Neurosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Minerva Neurosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 18 Stocks | 2.3% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2017 Stocks | 2.4% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | 0.00 | 1.00 |
| 2020-12-31 | 0.00 | 1.00 |
| 2019-12-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Minerva Neurosciences has not reported any payouts.
- Unable to verify if Minerva Neurosciences's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Minerva Neurosciences's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Minerva Neurosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Minerva Neurosciences has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $3,910,245 |
| AGE | 58 |
| TENURE AS CEO | 4.7 years |
CEO Bio
Dr. Rémy Luthringer, Ph.D., has been Executive Chairman of Minerva Neurosciences, Inc. since February 2018. Dr. Luthringer has been the Chief Executive Officer of Minerva Neurosciences, Inc. since November 2014 and served as its President from November 2014 to December 2017. Mr. Luthringer serves as Advisor at Index Ventures. He joined Index Ventures in 2010 and established the Geneva office. Dr. Luthringer serves as an Advisor at Medicxi Ventures. He serves as the Chief Medical Officer at the Index Life VI biotech fund raised by Index Ventures in 2012. He served as the Chief Scientific Officer at Minerva Neurosciences, Inc. He served as an Executive Vice President and Head of Research & Development at Minerva Neurosciences Inc. since March 2014. He has provided consulting services to Minerva Neurosciences since January 2011. He served as the Chief Medical Officer and Partner at Index Ventures since December 2010. He served as the Chief Executive Officer at Groupe FORENAP and FORENAP Pharma EURL. He served as the Chief Executive Officer and President at the FORENAP Institute for Research in Neurosciences and Neuropsychiatry from 2005 to September of 2010. He served as the Chief Executive Officer at one of the research institutes in neurosciences. He had advisory roles in several companies including the following: Funxional Therapeutics, Linguaflex and V-Watch. He has been a Director of Minerva Neurosciences, Inc. since November 2014. He serves as a Member of Scientific Advisory Board at Index Life VI. He has been a Member of the Scientific Advisory Board of Somnus Therapeutics, Inc. since November 2008. He was involved in several European grants and research programs focusing on development and validation of biomarkers or surrogate endpoints. He served on advisory boards of biotech as well as pharmaceutical companies and was involved in the development of more than 150 CNS active molecules and has carried out more than 700 clinical trials. He spent some years in clinical psychiatric practice. He focuses on investments in life sciences, healthcare infrastructure in Switzerland, France and United Kingdom. Dr. Luthringer received a Ph.D. in Neurosciences and in Clinical Pharmacology from University Louis Pasteur, France. He received a Masters Degree in Functional Explorations and Computer Engineering from University Paris VI, France and a obtained a Nursing Degree in Psychiatry from Rouffach Hosptial, France.
CEO Compensation
- Rémy's compensation has increased whilst company is loss making.
- Rémy's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Minerva Neurosciences management team in years:
- The tenure for the Minerva Neurosciences management team is about average.
Management Team
Rémy Luthringer
Executive Chairman & CEO
$4M
58
4.7 yrs
Rick Russell
President
$2M
55
1.6 yrs
Geoff Race
Executive VP
$2M
58
5.2 yrs
Devin Smith
Senior VP
$2M
51
1 yrs
Joe Reilly
Senior VP & COO
$1M
44
5 yrs
Fred Ahlholm
Senior VP & Chief Accounting Officer
$845K
53
5 yrs
William Boni
Vice President of Investor Relations & Corporate Communications
67
3.9 yrs
Michael Davidson
Chief Medical Officer
$3M
69
2.6 yrs
Jay Saoud
Senior VP and Head of Research & Development
60
Board of Directors Tenure
Average tenure and age of the Minerva Neurosciences board of directors in years:
- The average tenure for the Minerva Neurosciences board of directors is less than 3 years, this suggests a new board.
Board of Directors
Jan van Heek
Independent Director
$157K
70
5 yrs
Rémy Luthringer
Executive Chairman & CEO
$4M
58
1.4 yrs
Fouzia Laghrissi-Thode
Director
$153K
56
4.2 yrs
David Kupfer
Director
$150K
78
3.7 yrs
Bill Doyle
Lead Independent Director
$273K
57
1.4 yrs
Hans Hasler
Director
$153K
63
1.6 yrs
Jeri Hilleman
Independent Director
$241K
61
1 yrs
Who owns this company?
Recent Insider Trading
- More shares have been bought than sold by Minerva Neurosciences individual insiders in the past 3 months.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 01. Jul 19 | Buy | William Doyle | Individual | 27. Jun 19 | 27. Jun 19 | 3,500 | $5.50 | $19,250 | ||
| 27. Jun 19 | Buy | G. van Heek | Individual | 26. Jun 19 | 26. Jun 19 | 10,000 | $5.37 | $53,700 | ||
| 27. Jun 19 | Buy | Jeryl Hilleman | Individual | 26. Jun 19 | 26. Jun 19 | 1,000 | $5.25 | $5,250 | ||
| 27. Jun 19 | Buy | Hans Hasler | Individual | 26. Jun 19 | 26. Jun 19 | 10,000 | $5.60 | $56,000 | ||
| 27. Jun 19 | Buy | David Kupfer | Individual | 26. Jun 19 | 26. Jun 19 | 10,000 | $5.55 | $55,500 | ||
| 26. Jun 19 | Sell | Index Ventures | Company | 24. Jun 19 | 24. Jun 19 | -194,000 | $6.01 | $-1,166,794 | ||
| 21. Jun 19 | Sell | Index Ventures | Company | 19. Jun 19 | 20. Jun 19 | -110,818 | $4.44 | $-488,911 | ||
| 19. Jun 19 | Sell | Index Ventures | Company | 17. Jun 19 | 18. Jun 19 | -105,918 | $4.45 | $-470,730 | ||
| 18. Jun 19 | Sell | Index Ventures | Company | 17. Jun 19 | 17. Jun 19 | -56,243 | $4.45 | $-250,208 | ||
| 17. Jun 19 | Sell | Index Ventures | Company | 13. Jun 19 | 13. Jun 19 | -78,179 | $4.51 | $-352,442 | ||
| 13. Jun 19 | Sell | Index Ventures | Company | 11. Jun 19 | 12. Jun 19 | -60,051 | $4.78 | $-281,343 | ||
| 21. May 19 | Sell | Index Ventures | Company | 17. May 19 | 20. May 19 | -22,918 | $6.08 | $-137,896 | ||
| 16. May 19 | Sell | Index Ventures | Company | 14. May 19 | 16. May 19 | -134,828 | $7.05 | $-898,161 | ||
| 26. Dec 18 | Buy | William Doyle | Individual | 20. Dec 18 | 20. Dec 18 | 2,000 | $6.50 | $13,000 | ||
| 13. Dec 18 | Sell | Richard Russell | Individual | 12. Dec 18 | 12. Dec 18 | -3,117 | $7.96 | $-24,811 | ||
| 12. Dec 18 | Buy | William Doyle | Individual | 10. Dec 18 | 11. Dec 18 | 6,000 | $8.00 | $47,800 | ||
| 21. Nov 18 | Buy | William Doyle | Individual | 20. Nov 18 | 20. Nov 18 | 2,000 | $8.20 | $16,400 | ||
| 15. Oct 18 | Buy | William Doyle | Individual | 11. Oct 18 | 11. Oct 18 | 600 | $10.00 | $6,000 | ||
| 03. Oct 18 | Sell | Index Ventures | Company | 01. Oct 18 | 01. Oct 18 | -15,444 | $12.35 | $-190,747 | ||
| 01. Oct 18 | Sell | Index Ventures | Company | 27. Sep 18 | 28. Sep 18 | -66,273 | $12.62 | $-834,618 | ||
| 19. Sep 18 | Buy | William Doyle | Individual | 17. Sep 18 | 17. Sep 18 | 1,800 | $10.50 | $18,900 | ||
| 17. Sep 18 | Buy | William Doyle | Individual | 13. Sep 18 | 14. Sep 18 | 2,200 | $10.50 | $23,100 | ||
| 11. Sep 18 | Buy | William Doyle | Individual | 10. Sep 18 | 11. Sep 18 | 8,011 | $9.88 | $78,507 | ||
Management checks
We assess Minerva Neurosciences's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Minerva Neurosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own?
With a market capitalization of US$217m, Minerva Neurosciences is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Minerva Neurosciences NasdaqGM:NERV Ownership Summary, June 26th 2019 What Does The Institutional Ownership Tell Us About Minerva Neurosciences? … As you can see, institutional investors own 75% of Minerva Neurosciences.
Simply Wall St - – Full articleIntroducing Minerva Neurosciences (NASDAQ:NERV), The Stock That Slid 56% In The Last Three Years
The more recent news is of little comfort, with the share price down 39% in a year. … See our latest analysis for Minerva Neurosciences With zero revenue generated over twelve months, we don't think that Minerva Neurosciences has proved its business plan yet. … A Different Perspective Over the last year, Minerva Neurosciences shareholders took a loss of 39%.
Simply Wall St - – Full articleDoes The Minerva Neurosciences, Inc. (NASDAQ:NERV) Share Price Tend To Follow The Market?
In finance, Beta is a measure of volatility. … Volatility is considered to be a measure of risk in modern finance theory. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).
Simply Wall St - – Full articleWhat Type Of Shareholder Owns Minerva Neurosciences, Inc.'s (NASDAQ:NERV)?
Every investor in Minerva Neurosciences, Inc. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … With a market capitalization of US$327m, Minerva Neurosciences is a small cap stock, so it might not be well known by many institutional investors.
Simply Wall St - – Full articleRead This Before Selling Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares
So we'll take a look at whether insiders have been buying or selling shares in Minerva Neurosciences, Inc. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Minerva Neurosciences Insider Transactions Over The Last Year.
Simply Wall St - – Full articleBefore You Buy Minerva Neurosciences Inc (NASDAQ:NERV), Consider Its Volatility
Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.
Simply Wall St - – Full articleWhat Type Of Shareholder Owns Minerva Neurosciences Inc's (NASDAQ:NERV)?
Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Minerva Neurosciences is a smaller company with a market capitalization of US$411m, so it may still be flying under the radar of many institutional investors.
Simply Wall St - – Full articleDoes Minerva Neurosciences Inc (NASDAQ:NERV) Go Up With The Market?
The other type of risk, which cannot be diversified away, is market risk. … Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few. … Not every stock is exposed to the same level of market risk.
Simply Wall St - – Full articleMinerva Neurosciences Inc's (NASDAQ:NERV) Profit Outlook
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. … The company’s loss has recently broadened since it announced a -US$31.52m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$33.30m, moving it further away from breakeven … Many investors are wondering the rate at which NERV will turn a profit, with the big question being “when will the company breakeven?”
Simply Wall St - – Full articleMinerva Neurosciences Inc (NERV): Risks You Need To Consider Before Buying
See our latest analysis for NERV An interpretation of NERV's beta Minerva Neurosciences has a beta of 1.57, which means that the percentage change in its stock value will be higher than the entire market in times of booms and busts. … A high level of beta means investors face higher risk associated with potential gains and losses driven by market movements. … NERV, with its market capitalisation of USD $201.24M, is a small-cap stock, which generally have higher beta than similar companies of larger size.
Simply Wall St - – Full articleCompany Info
Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company’s lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIb clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company’ preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, NV for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Details
| Name: | Minerva Neurosciences, Inc. |
| NERV | |
| Exchange: | NasdaqGM |
| Founded: | 2007 |
| $254,836,325 | |
| 39,025,471 | |
| Website: | http://www.minervaneurosciences.com |
| Address: |
Minerva Neurosciences, Inc. 1601 Trapelo Road, Suite 286, Waltham, Massachusetts, 02451, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGM | NERV | Common Stock | Nasdaq Global Market | US | USD | 01. Jul 2014 | |
| DB | 4MN | Common Stock | Deutsche Boerse AG | DE | EUR | 01. Jul 2014 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/07/22 02:56 |
| End of day share price update: | 2019/07/19 00:00 |
| Last estimates confirmation: | 2019/06/25 |
| Last earnings filing: | 2019/05/06 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
